10 Den systemiske emtricitabineksponering (gennemsnit ± standardafvigelsen) steg fra 11, 8±2, 9 µg· t/ ml hos forsøgspersoner med normal nyrefunktion til 19, 9±1, 1, 25, 0±5, 7 og 34, 0±2, 1 µg· t/ ml hos patienter med henholdsvis mildt, moderat og svært nedsat nyrefunktion.
The systemic emtricitabine exposure (mean ± standard deviation) increased from 11.8±2.9 µg·h/ ml in subjects with normal renal function to 19.9±1.1, 25.0±5.7 and 34.0±2.1 µg·h/ ml, in patients with mild, moderate and severe renal impairment, respectively.